Radioligand therapies, which deliver small amounts of radioactive isotopes directly to cancer cells, are still waiting for their breakthrough moment. The technology has tremendous potential to deliver ...
This year, JPM 2026 took place again in San Francisco. Let’s look at predictions and trends forecast for 2026, according to ...
Detailed price information for Radiopharm Theranostics Limited ADR (RADX-Q) from The Globe and Mail including charting and trades.
Plus Therapeutics stock falls in premarket trading after pricing a $15 million public offering, with proceeds set for working capital as the company develops cancer treatments.
Collaboration combines Alloy’s antibody discovery and engineering platforms with Torpedo’s radiopharmaceutical development capabilities – including Terbium-161 – to advance next-generation oncology ...
Radiopharm Ventures, LLC, is a joint venture created in 2022 between MD Anderson Cancer Center and Radiopharm Theranostics Leading candidate Betabart, a monoclonal antibody targeting B7H3, has ...
HOUSTON, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the "Company”), a healthcare company ...
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, ...
Interim results from Phase 2b clinical trial of RAD 101 showed 92% of evaluable participants met the primary endpoint of MRI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results